An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer.

Joan JacobLiezl E FranciscoTreena ChatterjeeZhengdong LiangShraddha SubramanianQingyun J LiuJulie H RoweKendra S Carmon

Published in: British journal of cancer (2023)

This study provides the rationale for the future development of a GPR56-targeted ADC approach to potentially treat a large fraction of MSS CRC patients.

Keyphrases

cancer therapy
end stage renal disease
newly diagnosed
ejection fraction
fatty acid
prognostic factors
clinical trial
stem cells
magnetic resonance imaging
magnetic resonance
computed tomography